Anand Rohatgi

Anand Rohatgi, M.D., M.S.C.S., FACC, FAHA, is a Professor of Medicine in the Department of Internal Medicine's Division of Cardiology at UT Southwestern Medical Center. He specializes in preventive cardiology and serves as the Associate Program Director of UTSW's Cardiovascular Fellowship. Dr. Rohatgi is an active researcher focusing on novel biomarkers for cardiovascular risk prediction and is a principal investigator on multiple NIH-funded studies.

Dr. Rohatgi's educational background includes:

• Medical degree from Duke University School of Medicine
• Internal medicine residency at the University of Pennsylvania Health System
• Cardiology fellowship at UT Southwestern
• Master's degree in clinical science from UT Southwestern

Dr. Rohatgi's research primarily focuses on the role of high-density lipoproteins (HDL) in cardiovascular disease, particularly examining cholesterol efflux capacity and reverse cholesterol transport. His work explores how novel biomarkers can improve risk prediction for atherosclerosis and coronary artery disease. He has a special interest in high-risk populations, including those with diabetes and people of South Asian ancestry, investigating why these groups experience disproportionate cardiovascular risk. His research integrates epidemiological approaches with molecular mechanisms to identify new therapeutic targets.

Analysis of Dr. Rohatgi's recent publications reveals a consistent focus on HDL function and cholesterol metabolism as determinants of cardiovascular risk. His work spans basic mechanisms of cholesterol efflux, clinical applications of HDL measurements, and population studies examining ethnic and sex differences in cardiovascular biomarkers. A notable trend is his growing emphasis on South Asian populations and the unique cardiometabolic risk factors affecting this group, as evidenced by his NIH R01 grant focused on lipoprotein metabolism in South Asians using the MASALA cohort.

Dr. Rohatgi has received numerous professional recognitions:

• Fellow of the American College of Cardiology (FACC)
• Fellow of the American Heart Association (FAHA)
• Research awards from the American Heart Association

As an educator and mentor, Dr. Rohatgi serves as Associate Program Director of UTSW's Cardiovascular Fellowship and has received NIH K24 funding for 'Mentoring Patient-Oriented Research in Deep Lipid Phenotyping for Cardiovascular Disease.' His major research grants include three significant NIH awards: 'The Genetic and Molecular Basis of Cholesterol Efflux' (R01), 'Mentoring Patient-Oriented Research' (K24), and 'Lipoprotein Metabolism and Excess Cardiometabolic Risk in South Asians' (R01, 2022-2027). He also serves on several campus committees to enhance clinical research.

Dr. Rohatgi leads the Rohatgi Lab at the Harry S. Moss Heart Center, which focuses on elucidating the role of reverse cholesterol transport in atheroprotection and identifying drivers of cardiometabolic risk in high-risk groups. His lab utilizes resources like the MASALA cohort in the U.S. and the U.K. biobank cohort in Europe for population-based research. He serves as a reviewer for prestigious journals including The Lancet, JAMA, and Circulation, and is an Associate Editor for Circulation and on the Editorial Board for the Journal of Clinical Lipidology.